Betta Pharmaceuticals Co.Ltd(300558)
Independent opinions of independent directors on matters related to the 29th meeting of the third board of directors
In accordance with the guiding opinions on the establishment of independent director system in listed companies, the Listing Rules of GEM stocks of Shenzhen Stock Exchange, the self regulatory guidelines for listed companies of Shenzhen Stock Exchange No. 2 – standardized operation of GEM listed companies and other laws and regulations of China Securities Regulatory Commission, and Betta Pharmaceuticals Co.Ltd(300558) (hereinafter referred to as the “company”) In accordance with the working system of independent directors and other relevant provisions, as an independent director of the company, based on independent judgment and a realistic, serious and responsible attitude, We listened to the reports of relevant personnel and reviewed relevant materials on the proposal on investment in Wuhan Heyuan Biotechnology Co., Ltd. and related party transactions considered at the 29th meeting of the third board of directors of the company. After careful review and discussion, we made the following independent opinions:
We have carefully reviewed the proposal and relevant materials submitted by the company on this affiliated joint investment. This investment is conducive to expanding the company’s new drug innovation technology platform and accelerating the company’s strategic layout in the field of disease treatment. The transaction follows the general commercial terms and is in line with the company’s interests and development strategy. The valuation of this transaction is based on the R & D characteristics and stage characteristics of innovative drugs in the pharmaceutical industry, combined with the technical advantages and market potential of Heyuan biological product pipeline, and determined through consultation by all parties involved in the capital increase. The pricing is fair and follows the principle of marketization, and there is no situation that damages the interests of the company and shareholders, especially small and medium-sized shareholders. This proposal has been approved by us in advance before being submitted to the board of directors for deliberation. When voting on the proposal, Ding lieming, a related director, has withdrawn from voting. The company’s deliberation procedures for this proposal comply with relevant laws and regulations and the articles of association.
To sum up, we unanimously agree to this motion.
(there is no text below this page, and the next page is the signature page)
[there is no text on this page, which is the signature page of the independent opinions of Betta Pharmaceuticals Co.Ltd(300558) independent directors on matters related to the 29th meeting of the third board of directors] independent directors:
Jiangnan Cai Zhao Jun, Wang Wei, Huang Xinqi March 4, 2022
